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Abstract It is assumed that testosterone is an important
regulator of gender-related differences in ventricular
repolarization. Therefore, our aim was to study whether
serum levels of testosterone are associated with QTc, QT
and RR interval variation. Setting: two independent pop-
ulation-based cohort studies. Participants: 445 male par-
ticipants (C55 years) from the Rotterdam study cohort and
1,428 male participants from the study of health in Pom-
erania (SHIP) with an electrocardiogram who were ran-
domly sampled for assessment of serum testosterone at
baseline, after exclusion of participants with testosterone
altering drugs, QTc prolonging drugs or dig(it)oxin, left
ventricular hypertrophy and left and right bundle branch
block. Endpoints: length of the QTc, QT and RR intervals.
Analysis: linear regression model, adjusted for the two
individual studies and a pooled analysis of both studies.
The pooled analysis of the Rotterdam study and SHIP
showed that the QTc interval gradually decreased among
the tertiles (P value for trend 0.024). The third tertile
of serum testosterone was associated with a lower QTc
interval compared to the ﬁrst tertile [-3.4 ms (-6.5;
-0.3)]. However, the third tertile of serum testosterone was
not associated with a lower QT interval compared to the
ﬁrst tertile [-0.7 ms (-3.1; 1.8)]. The RR interval gradu-
ally increased among the tertiles (P value for trend 0.002)
and the third tertile of serum testosterone showed an
increased RR interval compared to the ﬁrst tertile [33.5 ms
(12.2; 54.8)]. In the pooled analysis of two population-
based studies, serum testosterone levels were not associ-
ated with the QT interval, which could be due to a lack of
power. Lower QTc intervals in men with higher serum
testosterone levels could be due to the association of serum
testosterone with prolongation of the RR interval.
Keywords Serum testosterone  Ventricular
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Introduction
There are well known gender-related differences in human
cardiac repolarization[1,2].This is demonstratedbya longer
heart-ratecorrectedQT(QTc)intervalinwomen,whichisthe
traditional clinical measurement for assessing the duration of
ventricular repolarization [3]. Prolongation of ventricular
repolarizationmayresultinearlyafterdepolarizations,which
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DOI 10.1007/s10654-009-9406-zin turn may induce re-entry and thereby provoke Torsade de
Pointes and fatal ventricular arrhythmias [4–7].
The gender differences in the QTc interval are not
present in young children, whereas at the time of onset of
puberty the duration of the QTc interval in boys shortens,
which results in a longer QTc interval in adult women
compared to men [8–10]. These gender differences remain
detectable until around the age of 50 years [10]. Since the
period between puberty and 50 years of age coincides with
the highest circulating levels of androgens in males, male
sex hormones may play a role in the shorter QTc interval in
men. Furthermore, virilized women exhibit QTc intervals
similar to those of healthy men, whereas castrated men had
QTc intervals similar to those of normal women [11].
Testosterone therapy also reduces QT dispersion in men
with congestive heart failure [12].
These data suggest that testosterone might be an
important regulator of ventricular repolarization, which
might explain the gender-related differences in ventricular
repolarization. Therefore, our aim was to study whether
testosterone is associated with QTc, QT and RR interval
duration. Since bio-available testosterone decreases with
age, we studied this association in two cohorts. First, in a
cohort of elderly (the Rotterdam study) and second, in a
cohort with a younger mean age (the Study of Health In
Pomerania (SHIP)) [13].
Methods
Setting and study design
Rotterdam study
The Rotterdam study is a prospective population-based
cohort study, which started with a baseline visit between
1990 and 1993. The Medical Ethics Committee of the
Erasmus Medical Center, Rotterdam, the Netherlands,
approvedthestudy.AllinhabitantsofOmmoord,asuburbof
Rotterdam, aged 55 years and over, were invited to partici-
pate (n = 10,275). Of them, 7,983 (78%) gave their written
informed consent and took part in the baseline examination.
Objectives and methods of the Rotterdam study have been
described in detail elsewhere [14, 15]. At baseline, all par-
ticipants were visited at home for a standardized question-
naire,and7,151weresubsequentlyexaminedattheresearch
center. The cohort is continuously monitored for major
morbidity and mortality through linkage with general prac-
titioner and municipality records. Drug prescriptions dis-
pensed to participants by automated pharmacies are
routinely stored in the database since January 1, 1991.
All male cohort members of the Rotterdam study
(n = 3,105), who had an ECG as well as serum testosterone
and dehydroepiandrosterone sulfate (DHEAS) measure-
ments at baseline were enrolled in the study population.
Digitally stored ECGs were available for 2,200 male par-
ticipants at the time of the ﬁrst visit. Missing ECGs were
mainly due to temporary technical problems with ECG
recording. Androgen status was assessed in different ran-
dom subsets of these males. Male participants with an ECG
and with both a serum testosterone measurement and a
DHEAS measurement (n = 540) were included. Partici-
pants who received anabolic steroids (anatomic therapeuti-
cal chemical (ATC) code A14A; n = 1) were excluded.
None of the participants received sexual hormones (ATC
code G03), testosterone 5a-reductase inhibitors (ATC code
G04CB), sexual hormone antagonists (ATC code L02B) or
had a pacemaker. Participants who used digoxin (n = 25),
which is a QTc shortening agent, or QTc prolonging drugs
(n = 6) as well as persons with evidence of left ventricular
hypertrophy (n = 36) or left (n = 13) and right bundle
branch block (n = 36) were excluded, since these condi-
tions are associated with an altered QTc interval [16, 17].
Overall, 445 participants were included in the Rotterdam
study population.
The Study of Health In Pomerania
The Study of Health In Pomerania is a cross-sectional
population-based study in West Pomerania, a region in the
northeast of Germany. The total population of West
Pomerania selected for SHIP comprised 212,157 inhabit-
ants. A two-stage cluster sampling method adopted from
the WHO MONICA Project Augsburg, Germany yielded
12, 5 years age strata (20–79 years) for both genders, each
including 292 individuals [18]. The sampling was per-
formed from population registries where all German citi-
zens are registered. Data collection started in October 1997
and was ﬁnished in March 2001. The net sample comprised
6,267 eligible subjects. Finally, 4,310 subjects (69%) par-
ticipated. The study was monitored by a board of inde-
pendent scientists. All participants gave written informed
consent. The study conformed to the principles of the
Declaration of Helsinki as reﬂected by an a priori approval
of the Ethics Committee of the University of Greifswald.
Use of medication at baseline was recorded by a computer-
aided method using the ATC code.
All male cohort members of SHIP (n = 2,118) with
ECG, testosterone and DHEAS measurements at baseline
were enrolled in the study population. Digitally stored
ECGs were available for 1,826 male participants at the
time of the ﬁrst visit. Male participants with an ECG and
with both a testosterone and a DHEAS measurement
(n = 1,677) were included. Participants who received
sexual hormones (ATC code G03) (n = 3), testosterone 5a
reductase inhibitors (ATC code G04CB; n = 4) or sexual
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123hormone antagonists (ATC code L02B; n = 3) were
excluded. None of the participants reported to receive ana-
bolic steroids (ATC code A14A). Furthermore, participants
who used digoxin (n = 5) or digitoxin (n = 153), QTc
prolonging drugs (n = 13), persons with a pacemaker
(n = 15),aswellaspersonswithevidenceofleftventricular
hypertrophy (n = 4) or left (n = 1) and right bundle branch
block (n = 48) were excluded. Overall, 1,428 participants
were included in the SHIP study population.
QTc, QT and RR interval
The endpoints of the study were the lengths of the QTc,
QT and RR intervals in ms. A 12-lead resting ECG was
recorded with an ACTA electrocardiograph (ESAOTE,
Florence, Italy) at a sampling frequency of 500 Hz and
stored digitally. All ECGs (both from the Rotterdam study
as well as SHIP) were centrally processed in Rotterdam
using the modular ECG analysis system (MEANS) to
obtain ECG measurements, in agreement with the FDA
guidance for clinical evaluation of QT/QTc interval pro-
longation [19]. The MEANS program has been evaluated
and validated extensively [20–23]. In one of these vali-
dation studies, ECGs with selected abnormalities were
analyzed by ﬁve cardiologists and 11 different computer
programs of which MEANS performed as one of the best
[23]. In a study in which QT intervals by manual mea-
surement were compared with QT measurement by ECG
machines, manual and automated measurements generated
similar numerical results in three studies in healthy vol-
unteers, which all included a positive control [24].
MEANS determines common onsets and offsets for all 12
leads together on one representative averaged beat, with
the use of template matching techniques [21]. The QT
interval is determined from the start of the QRS complex
until the end of the T wave. To adjust for heart rate, Ba-
zett’s formula (QTc = QT/HRR) was used [25]. The RR
interval was taken as the median of the RR intervals in the
recording. Additionally, the MEANS program determines
left ventricular hypertrophy and left and right bundle
branch block.
Steroids
Rotterdam study
At baseline, non-fasting blood samples were obtained.
Time of sampling was recorded. Testosterone and DHEAS
were estimated using coated tube or double antibody RIAs,
respectively, purchased from diagnostic systems laborato-
ries [26].
SHIP
At baseline, non-fasting blood samples were obtained. Time
of sampling was recorded. Testosterone and DHEAS were
measured using competitive chemiluminescent enzyme
immunoassays on an Immulite 2500 analyzer (DPC
Biermann GmbH, Bad Nauheim, Germany).
Covariates
Rotterdam study
Hypertension was identiﬁed through the use of antihyper-
tensive medication and/or the assessment of blood pressure
measurements, according to the guidelines of the World
Health Organisation [27]. Prevalence and incidence of
myocardial infarction were assessed as previously descri-
bed [28, 29]. Diabetes mellitus was deﬁned as the use of
blood glucose–lowering medication and/or a non-fasting
serum glucose level of 11.1 mmol/l or higher and/or fasting
serum glucose levels C7 mmol/l [30]. Prevalence and
incidence of heart failure were assessed by the presence of
suggestive signs and symptoms as previously described
[31, 32]. Potassium and calcium were measured by means
of a Microlyte device. During the home interview, smoking
status and use of alcohol were assessed. Creatinine clear-
ance was computed with the Cockroft Gault method. Renal
failure was deﬁned by the internationally accepted criterion
of a GFR below 60 ml/min [33]. Gamma-glutamyl
transferase (GGT), aspartate-amino transferase (ASAT),
alanine-amino transferase (ALAT) levels above the
upper limit of normal were used to determine hepatic
dysfunction.
SHIP
Hypertension was identiﬁed through the use of antihy-
pertensive medication and/or the assessment of blood
pressure measurements, according to the guidelines of
the World Health Organisation [27]. Diabetes mellitus
and myocardial infarction were deﬁned as self-reported
physician’s diagnosis. Determination of calcium was
performed by a colorimetric assay and potassium by ion-
selective electrodes (Roche/Hitachi 717; Roche Diagnos-
tics GmbH, Mannheim, Germany). During the home
interview, smoking status and use of alcohol were asses-
sed. Creatinine clearance was computed with the Cockroft
Gault method. Renal failure was deﬁned by the interna-
tionally accepted criterion of a GFR below 60 ml/min
[33]. GGT, ALAT and ASAT were used to determine
hepatic dysfunction.
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123Statistical analysis
The association between the QTc, QT, RR intervals and
testosterone was assessed through linear regression with
log-transformed testosterone and testosterone measure-
ments divided in tertiles. Since DHEAS was associated
with both the QTc and the RR interval, we adjusted all
analyses for DHEAS. Furthermore, all analyses were
adjusted for age, time of blood withdrawal (recorded in
hours and minutes), hypertension, myocardial infarction,
diabetes mellitus, potassium, calcium and in the Rotterdam
study also for heart failure.
First, a linear regression analysis was conducted with
QTc, QT (adjusted for the length of the RR interval) and
RR interval as dependent and testosterone as independent
variables for the Rotterdam study and SHIP separately.
Second, we conducted a pooled analysis of the Rotterdam
study and SHIP. Furthermore, we performed several sen-
sitivity analyses: ﬁrst, by stratiﬁcation for age. Second, in
additional analyses we adjusted for smoking, alcohol
abuse, renal failure, hepatic failure and use of beta-block-
ers. All analyses were performed using SPSS for Windows
version 15.0 (Chicago, Illinois, USA).
Results
Subject characteristics
The baseline characteristics of the participants are pre-
sented in Table 1. The mean age of the study population of
the Rotterdam study was 68.0 years [standard deviation
(SD) 7.8 years]. The mean testosterone level was
11.3 nmol/l (SD = 3.7). The mean age of the study pop-
ulation of SHIP was 49.1 years (SD 16.0 years). Mean
testosterone levels were 17.0 nmol/l (SD = 5.9).
Androgens and QTc interval
The mean duration of the QTc interval was approximately
similar in both studies, the mean duration of the QT and
RR interval was slightly longer in the Rotterdam study than
in SHIP (Table 1). Comparison of the highest testosterone
tertile with the lowest tertile showed no signiﬁcant asso-
ciation between testosterone and QTc [-5.9 ms (95%
CI- 13.8; 2.1) and -2.9 ms (95% CI- 5.9; 0.1) respectively]
nor with the QT interval [–2.4 ms (95% CI- 8.8; 4.0) and
-0.6 ms (95%CI- 3.0; 1.8) respectively] in the Rotterdam
study and SHIP separately (Table 2). The logarithmic
transformation of testosterone was associated with the QTc
interval in SHIP [-7.9 ms (95% CI- 15.3; -0.6)].
In SHIP, the RR interval increased gradually with
increasing testosterone levels (P value for trend 0.004) and
the second and third tertiles of testosterone had longer RR
intervals compared to the ﬁrst tertile [24.0 ms (95% CI 3.8;
44.1) and 31.3 ms (95% CI 10.3; 52.3) respectively]. The
logarithmic transformation of testosterone was associated
with the RR interval in both the Rotterdam study and SHIP
[149.8 ms (95% CI 30.6; 269.1) and 55.9 ms (95% CI 5.2;
106.6) respectively].
Pooled analysis
There was a gradual decrease of the QTc interval among
the tertiles (P value for trend 0.024), while the third tertile
of testosterone was signiﬁcantly associated with the QTc
interval compared to the ﬁrst tertile [-3.4 ms (95%
CI- 6.5; -0.3); Table 3]. Compared to the ﬁrst tertile of
testosterone, the third tertile was not associated with the
QT interval [–0.7 ms (95% CI- 3.1; 1.8)].
There was a gradual increase of the RR interval among
the tertiles (P value for trend 0.002), while the third tertile
of testosterone was signiﬁcantly associated with the RR
interval compared to the ﬁrst tertile [33.5 ms (95% CI 12.2;
54.8)]. Sensitivity analyses revealed no effect modiﬁcation
by age. Additional adjustment for smoking, alcohol, renal
failure, hepatic failure or use of beta-blockers did not
change the estimates.
Discussion
In this pooled analysis of two population-based studies, we
found that serum testosterone levels were associated with
shortening of the QTc interval and prolongation of the RR
Table 1 Baseline characteristics of study population
Rotterdam study SHIP
Number of participants 445 1,428
Age (years, mean, SD) 68.0 (7.8) 49.1 (16.0)
Mean QTc interval (ms; SD) 423.2 (25.0) 423.5 (24.4)
Mean QT interval (ms; SD) 398.2 (28.6) 394.1 (29.9)
Mean RR interval (ms; SD) 896.2 (156.7) 876.0 (156.2)
Body mass index (kg/m
2; SD) 26.6 (3.4) 27.7 (4.2)
Diabetes mellitus (n, %) 50 (11.2) 95 (6.7)
Myocardial infarction (n, %) 84 (18.9) 59 (4.1)
Hypertension (n, %) 111 (24.9) 594 (41.6)
Heart failure (n, %) 7 (1.6) –
Mean potassium (mmol/l; SD) 4.1 (0.3) 4.1 (0.3)
Mean calcium (mmol/l; SD) 2.4 (0.1) 2.4 (0.1)
Mean DHEAS (lmol/l; SD) 4.3 (2.7) 5.3 (3.3)
Mean testosterone (nmol/l; SD) 11.3 (3.7) 17.0 (5.9)
SD standard deviation
DHEAS dehydroepiandrosterone sulfate
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123interval in men, whereas we did not ﬁnd an association
between serum testosterone levels and the uncorrected QT
interval, which could be due to a lack of power. Earlier, it
has been suggested that the shorter QTc interval in men
than in women may be explained by the fact that testos-
terone inﬂuences repolarization by its effect on Ca
2? and
K
? channels, as well as on hERG K
? channels [34]. Since
the QT interval was not signiﬁcantly associated with serum
testosterone, our ﬁndings could suggest that the difference
in the QTc interval in men is mainly due to the underlying
association with the RR interval. Since QTc is calculated
by Bazett’s formula, an increase in RR interval will lead to
a shorter QTc interval. However, the QTc interval calcu-
lated by Bazett’s formula is clinically relevant and is often
used in epidemiological and clinical investigations. The
QTc interval has been associated with an increased risk of
all-cause mortality and sudden cardiac death [1, 2]. In
addition, low testosterone levels are associated with an
increased risk of all-cause mortality in men, [3] which is
consistent with our ﬁndings of an increased QTc interval
Table 2 Association of testosterone with QTc, QT and RR interval
Testosterone QTc-interval in ms
(95% CI)
a
QT-interval in ms
(95% CI)
b
RR-interval in ms
(95% CI)
a
Rotterdam study (n = 445) Log-transformation -6.5 (-23.7; 10.8) 5.9 (-8.2; 20.1) 149.8 (30.6; 269.1)
Tertiles
1 Reference Reference Reference
2 3.8 (-4.1; 11.7) 5.5 (-0.8; 11.9) 29.2 (-27.3; 85.8)
3 -5.9 (-13.8; 2.1) -2.4 (-8.8; 4.0) 42.4 (-14.3; 99.2)
P value for linear trend 0.132 0.419 0.143
SHIP (n = 1,428) Log-transformation 27.9 (215.3; 20.6) -3.4 (-9.2; 2.4) 55.9 (5.2; 106.6)
Tertiles
1 Reference Reference Reference
2 -0.7 (-3.6; 2.2) 1.5 (-0.8; 3.9) 24.0 (3.8; 44.1)
3 -2.9 (-5.9; 0.1) -0.6 (-3.0; 1.8) 31.3 (10.3; 52.3)
P value for linear trend 0.061 0.623 0.004
CI conﬁdence interval
a Adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, dehydroepiandrosterone
sulfate (DHEAS) and in the Rotterdam Study also for heart failure
b Adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, DHEAS, RR interval and
in the Rotterdam study also for heart failure
Testosterone in nmol/l. For the Rotterdam study the tertiles were deﬁned as (1) B9.9; (2) 10.0–12.6; (3) C12.7. For SHIP the tertiles were deﬁned
as (1) B13.9; (2) 14.0–18.6; (3) C18.7
The bold values indicate signiﬁcance at P\0.05
Table 3 Association of testosterone with QTc, QT and interval: pooled analysis of the Rotterdam study and SHIP (n = 1,873)
Testosterone QTc-interval in ms (95% CI)
a QT-interval in ms (95% CI)
b RR-interval in ms (95% CI)
a
Log-transformation 28.1 (214.8; 21.4) -3.1 (-8.4; 2.3) 62.5 (15.7; 109.2)
Tertiles
1 Reference Reference Reference
2 -0.7 (-3.6; 2.1) 0.5 (-1.8; 2.8) 10.8 (-9.1; 30.8)
3 -3.4 (-6.5; -0.3) -0.7 (-3.1; 1.8) 33.5 (12.2; 54.8)
P value for linear trend 0.024 0.529 0.002
CI conﬁdence interval
a Adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, dehydroepiandrosterone
sulfate (DHEAS) and cohort
b Adjusted for age, time of blood withdrawal, diabetes, hypertension, myocardial infarction, potassium, calcium, BMI, RR interval, DHEAS and
cohort
Testosterone in nmol/l. The tertiles were deﬁned as (1) B12.5; (2) 12.6–17.3; (3) C17.4
The bold values indicate signiﬁcance at P\0.05
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123and decreased RR interval in males with low testosterone
levels. The use of testosterone supplementation is
increasing, [4] in spite of limited knowledge on beneﬁts
and long-term safety and therefore it is important to know
the effects of endogenous testosterone levels.
The gender differences in the QTc interval remain
detectable until around the age of 50 years [10], this could
be due to the fact that bio-available testosterone decreases
with age [13]. In SHIP and the pooled analyses the direction
of change was as expected for the QTc and RR-adjusted QT
interval. In the Rotterdam study, however, the direction of
change differed, which could be due to limited power. In
addition, we did not ﬁnd a signiﬁcant association with the
RR interval in the Rotterdam study, which could also be due
to limited power. It is well known that women have a longer
QTc interval than men, [2] whereas the uncorrected QT
intervals are rather similar in men and women [10]. Since
women have a faster heart rate, and therefore shorter RR
intervals compared to men, women have a prolonged QTc
interval when the same heart rate correction formula is
applied. Recently it has been demonstrated in eleven hy-
pogonadic men, that the difference in the heart-rate-inde-
pendent QT interval duration is dependent on testosterone
levels [35]. The gender differences in the RR interval
remain after autonomic blockade, which suggests a possible
gender-related difference in sino-atrial node function [36].
However, this difference appears to be related to a differ-
ence in maximum exercise capacity between men and
women rather than to intrinsic sinus node gender-related
differences [36]. Since androgen levels increase in response
to exercise [37], the increased RR interval in men with high
testosterone levels could be due to increased exercise
capacity, which affects the sino-atrial node function.
Our investigation has several strengths that include the
population-based design of participating studies and the
central ECG data management, which facilitates best
comparability between both studies. Although we did not
use the complete population in the Rotterdam study,
selection bias is unlikely because the characteristics of the
study population were comparable to the baseline charac-
teristics of the whole population of the Rotterdam study.
Furthermore, information bias is unlikely because data were
gathered prospectively and because the use of digital ECG
recordings all measured using the automatic MEANS sys-
tem likely reduced intra- and interobserver variability in the
assessment of the QTc, QT and RR intervals. Confounding
was minimized by adjusting for most known risk factors.
However, our study has also some limitations. Because of
the cross-sectional design we cannot exclude that QTc
shortening or RR interval prolongation was already present
in some participants before the decrease of testosterone.
Several measurements within a person would be needed to
assess intra-individual differences. Therefore, the results
from this study should be conﬁrmed with longitudinal data
from other large cohorts. Another limitation of our study is
that repeated blood sampling in men with initially low
serum testosterone levels is recommended to conﬁrm
androgen deﬁciency [38], but this and other epidemiologic
studies [39–42] were based on a single measurement of
serum testosterone. In addition, two different methods were
used to measure testosterone levels. However, as can be
expected because of the higher average age, testosterone
levels were somewhat lower in the Rotterdam study
(Table 1), which is in agreement with the fact that testos-
terone levels decrease with age [5]. The results of the
pooled analyses did not substantially change after adjust-
ment for age. In addition, the direction of change of the
QTc and RR interval were comparable and as expected
(Table 2).
However, misclassiﬁcation of men with low serum tes-
tosterone levels would be expected to underestimate, not
overestimate associations.
Conclusion
We demonstrated in two population-based studies that
serum testosterone is associated with shortening of the QTc
interval and prolongation of the RR interval in men,
whereas we did ﬁnd a minor non-signiﬁcant association
between serum testosterone levels and the QT interval,
possibly due to a lack of power. The fact that the strongest
decrease was in the clinically relevant QTc interval in men
is partly explained by the effect of RR-prolongation in the
denominator of Bazett’s formula for the QTc-interval.
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